Clinical Trials Logo

Mild Alzheimer's Disease clinical trials

View clinical trials related to Mild Alzheimer's Disease.

Filter by:

NCT ID: NCT06058234 Recruiting - Clinical trials for Mild Alzheimer's Disease

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

Start date: July 6, 2023
Phase:
Study type: Observational

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

NCT ID: NCT05872243 Recruiting - Clinical trials for Mild Alzheimer's Disease

pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness and safety of rTMS treatment under the guidance of personalized Brain Functional Sectors (pBFS) for the cognitive ability of patients with mild Alzheimer's disease.

NCT ID: NCT05417555 Recruiting - Clinical trials for Mild Cognitive Impairment

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

LIFUP-MCIAD
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to investigate whether Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting a part of the brain involved in memory will have an affect on brain activity and whether it may improve memory in people with Mild Cognitive Impairment and Mild Alzheimer's Disease. The main questions the study seeks to answer are: 1. Can LIFUP increase brain activity in the targeted area? 2. Can LIFUP improve memory in people with MCI and mild AD? 3. Can LIFUP improve connectivity of memory networks in the brain? Participants in this study will complete MRIs and memory testing, and receive Low Intensity Focused Ultrasound to a part of their brain involved in memory (the entorhinal cortex).

NCT ID: NCT05233774 Completed - Clinical trials for Mild Alzheimer's Disease

Lomecel-B Effects on Alzheimer's Disease

CLEARMIND
Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

Dementia resulting from AD is associated with vascular function decline and involves a pro-inflammatory state. In our Phase 1 trial, Lomecel-B treatment met the primary safety endpoint, with no safety concerns, and showed potential to improve clinical assessments. Mechanistically, Lomecel-B treated subjects had higher serum concentrations of pro-vascular and anti-inflammatory biomarkers relative to placebo. This trial builds upon those preliminary Phase 1 results, and is designed to evaluate the safety profile of multiple infusions of Lomecel-B, and to investigate provisional efficacy of single dosing versus multiple dosing of Lomecel-B on cognitive function and biomarkers in AD subjects.

NCT ID: NCT05032482 Withdrawn - Clinical trials for Mild Alzheimer's Disease

WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease

WAVE-AD
Start date: December 2023
Phase: N/A
Study type: Interventional

This is a double- blind, randomized controlled trial with an open label extension designed to evaluate the safety and potential efficacy of a non-invasive brainstem neuromodulation device for treating symptoms associated with Alzheimer's disease (AD).

NCT ID: NCT03752294 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Start date: November 2018
Phase: Phase 1
Study type: Interventional

A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild Alzheimer's Disease.

NCT ID: NCT03234686 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Deferiprone to Delay Dementia (The 3D Study)

Start date: January 19, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Prodromal Alzheimer's Disease (pAD) and Mild Alzheimer's Disease (mAD). In this phase 2 study, the investigators aim to determine whether Deferiprone (15 mg/kg BID orally) slows cognitive decline in Alzheimer's patients. As secondary outcomes, safety and iron levels in the brain will be evaluated.

NCT ID: NCT03186989 Completed - Clinical trials for Mild Alzheimer's Disease

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Start date: October 12, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease

NCT ID: NCT01548287 Completed - Clinical trials for Mild Cognitive Impairment

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Start date: April 2012
Phase: Phase 2
Study type: Interventional

This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.

NCT ID: NCT01482013 Terminated - Clinical trials for Mild Cognitive Impairment

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

Start date: October 2011
Phase: Phase 1
Study type: Interventional

This is a safety and tolerability study investigating the effect of HPP854 in subjects with mild cognitive impairment or a diagnosis of mild Alzheimer's disease. The study will assess the pharmacokinetic and pharmacodynamic relationships of HPP854 in plasma, pharmacodynamic relationship in cerebral spinal fluid and plasma concentration profiles for Amyloid-Beta.